BioPharma Dive December 6, 2024
The expansion of a newly acquired facility in Wisconsin will help Lilly ramp up production of injectable drugs like its fast-selling Zepbound.
Eli Lilly will spend $3 billion to expand a manufacturing facility in Wisconsin it bought in April, adding new capabilities to produce injectable medicines like its fast-selling weight loss and diabetes drugs Zepbound and Mounjaro, the company said Thursday.
The expansion of the Kenosha County facility will be Lilly’s “single largest U.S. manufacturing investment” outside of its home state of Indiana, said Edgardo Hernandez, the head of the company’s manufacturing operations, in a statement.
Lilly will acquire additional land and an adjacent warehouse in the deal, which will add 750 employees to the 100 already working at the...
Today's Sponsors
Today's Sponsor